Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide

Dana E. RollisonDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA; Correspondence[email protected]

Rami KomrokjiDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA;

Ji-Hyun LeeBiostatistics Core, University of New Mexico Cancer Center, Albuquerque, NM, USA;

Shalaka HamprasDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA;

William FulpDepartment of Biostatistics, Moffitt Cancer Center, Tampa, FL, USA;

Kate FisherDepartment of Biostatistics, Moffitt Cancer Center, Tampa, FL, USA;

Rachid BazDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA;

Taiga NishihoriDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA;

Qiang XuCelgene Corporation, Summit, NJ, USA;

Marta OlesnyckyjCelgene Corporation, Summit, NJ, USA;

Laurie KenvinCelgene Corporation, Summit, NJ, USA;

Robert KnightCelgene Corporation, Summit, NJ, USA;

Daniel SullivanDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA;

Melissa AlsinaDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA;

William DaltonDeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center/M2GEN, Tampa, FL, USA

Kenneth H. ShainDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA;

References